Our product: Stroke is the most common cause of permanent disability in adults, and the second most common cause of death in the Western world. Today, people who suffer a stroke can be cured if they receive the right treatment in time. Unfortunately, most arrive too late. We hope to change that with Stroke Alarm — a wearable aid for patients with elevated stroke risk. Do you manage patients with increased risk of suffering a stroke? Right now, we offer the Swedish healthcare the opportunity to let their patients test Stroke Alarm. Please visit our webpage for more information about Stroke Alarm, the pilot and how to sign up. Stroke Alarm is a medical device, developed and manufactured by Uman Sense AB in Sweden. Stroke Alarm is CE-marked as a medical device in Europe. . . . Our company: Uman Sense is an MedTech innovation company, a spin-off from Lund University. We work to improve the lives of people through modern mobile solutions to medical challenges. With the patient in focus, we create innovative solutions at the intersection of medicine, mathematics, and mobile technology. We believe that our strategy creates new opportunities for healthcare to offer the best possible health care. Uman Sense AB is ISO 13485 certified. Uman Sense is a registered European trademark (EUTM) and a registered trademark in the United States (USPTO).
Extern länk för Uman Sense
Medicon Village Scheeletorget 1
Lund, 223 81, SE
Uman Sense omdelade detta
Docent på Lunds Universitet och överläkare på Skånes universitetssjukhus. Medgrundare till Uman Sense AB
Excellent presentation by Dr Alex Solich on how they transformed the stroke service in Örebro from the worst to the best in Sweden and among the best in Europe at the Let’s raise the bar - meeting in Milan in front of a large audience of neuroInterventionalists from all over Europe.
Dear Raj! Thank you for sharing this work and thank you Stephanie Hench and the team at Siemens Healthineers for inviting me to share some of our experiences with the new photon counting CT technology unleashed by the Naeotom Alpha! What a wonderful opportunity to be with you all at ESMINT in Marseille, and what a joy to be working in a field that has seen so much progress in the last few years!!
Pleased to share this article from our latest journal, Oruen The CNS Journal Volume 9 Issue 2: Clinical Advantages of NAEOTOM Alpha and ARTIS icono for Neurovascular Disease with Dr. Johan Wassélius Siemens Healthineers Direct link to read article: https://cutt.ly/hwDwjKBK #OruenCNSJournal #ESMINT2023 #INR #Oruen
Senaste finansieringsrunda
Okänd serie1 179 647,00 US$
Investerare